Towards therapeutic antibodies to membrane oncoproteins by a robust strategy using rats immunized with transfectants expressing target molecules fused to green fluorescent protein

Cancer Science

Volumn 102, Issue 1, 2011, Pages 25-35

  Masuko, Takashi ^a   Ohno, Yoshiya ^b   Masuko, Kazue ^a   Yagi, Hideki ^a   Uejima, Shinya ^a   Takechi, Masayuki ^a   Hashimoto, Yoshiyuki ^c  

^a KINKI UNIVERSITY   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

^c TOHOKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARRIER PROTEIN; CD71 ANTIGEN; EXCITATORY AMINO ACID TRANSPORTER; G PROTEIN COUPLED RECEPTOR; GANGLIOSIDE GD2; GREEN FLUORESCENT PROTEIN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; ONCOPROTEIN; RECOMBINANT PROTEIN; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR 1; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANTIBODY LIBRARY; ANTIGEN DETECTION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER IMMUNOTHERAPY; CELL VIABILITY; DRUG PROTEIN BINDING; DRUG TARGETING; HUMAN; HYBRIDOMA; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD44; CELL LINE; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNIZATION; MEMBRANE PROTEINS; ONCOGENE PROTEINS; PEPTIDE LIBRARY; RATS; RECEPTORS, TRANSFERRIN; RECOMBINANT FUSION PROTEINS; TRANSFECTION;

EID: 78650226701     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01741.x     Document Type: Review

References (80)

1. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-7.
2. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006; 6: 343-57.
3. Hauptrock B, Hess G. Rituximab in the treatment of non-Hodgkin's lymphoma. Biologics 2008; 2: 619-33.
4. Keating MJ, Dritselis A, Yasothan U, Kirkpatrick P. Ofatumumab. Nat Rev Drug Discov 2010; 9: 101-2.
5. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-54.
6. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009; 9: 463-75.
7. Burstein HJ, Kuter I, Campos SM et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001; 19: 2722-30.
8. Gianni L, Eiermann W, Semiglazov V et al. Nonadjuvant chemotherapy with trastuzumab followed by adjuvant trasutuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010; 375: 377-84.
9. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. New Engl J Med 2004; 351: 337-45.
10. Chung KY, Shia J, Kemeny NE et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803-10.
11. Tol J, Koopman M, Cats A et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Eng J Med 2009; 360: 563-72.
12. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391-400.
13. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl J Med 2004; 350: 2335-42.
14. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008; 8: 579-91.
15. Ishida T, Ueda R. CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci 2006; 97: 1139-46.
16. Burgess T, Coxon A, Meyer S et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res 2006; 66: 1721-9.
17. Nilsson K, Klein G, Henle W, Henle G. The establishment of lymphoblastoid lines from adult and fetal human lymphoid tissue and its dependence on EBV. Int J Cancer 1971; 8: 443-50.
18. Clackson T, Hoogenboom HR, Griffiths AD, Winter G. Making antibody fragments using phage display libraries. Nature 1991; 352: 624-8.
19. Seo H, Masuoka M, Murofushi H, Takeda S, Shibata T, Ohta K. Rapid generation of specific antibodies by enhanced homologous recombination. Nat Biotechnol 2005; 23: 731-5.
20. Irie RF, Morton DL. Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc Natl Acad Sci USA 1986; 83: 8694-8.
21. Kurosawa G, Akahori Y, Morita M et al. Comprehensive screening for antigens overexpressed on carcinomas via isolation of human mAbs that may be therapeutic. Proc Natl Acad Sci USA 2008; 105: 7287-92.
22. Buerstedde JM, Reynaud CA, Humphries EH, Olson W, Ewert DL, Weill JC. Light chain gene conversion continues at high rate in an ALV-induced cell line. EMBO J 1990; 9: 921-7.
23. Wang W, Seki M, Narita Y et al. Possible association of BLM in decreasing DNA double strand breaks during DNA replication. EMBO J 2000; 19: 3428-35.
24. Schmid M, Nanda I, Guttenbach M et al. First report on chicken genes and chromosomes 2000. Cytogenet Cell Genet 2000; 90: 169-218.
25. Shimomura O. Discovery of green fluorescent protein (GFP) (Nobel Lecture). Angew Chem Int Ed Engl 2009; 48: 5590-602.
26. Bruggemann M, Free J, Diamond A, Howard J, Cobbold S, Waldmann H. Immunoglobulin heavy chain locus of the rat: striking homology to mouse antibody genes. Proc Natl Acad Sci USA 1986; 83: 6075-9.
27. Aguilar BA, Gutman GA. Transcription and diversity of immunoglobulin lambda chain variable genes in the rat. Immunogenetics 1992; 37: 39-48.
28. Gibbs RA, Weinstock GM, Metzker ML et al. Genome sequence of the Brown Norway rat yields insights into mammalian evolution. Nature 2004; 428: 493-521.
29. Spieker-Polet H, Sethupathi P, Yam PC, Knight KL. Rabbit monoclonal antibodies: generating a fusion partner to produce rabbit-rabbit hybridomas. Proc Natl Acad Sci USA 1995; 92: 9348-52.
30. Nakamura N, Shuyama A, Hojyo S et al. Establishment of a chicken monoclonal antibody panel against mammalian prion protein. J Vet Med Sci 2004; 66: 807-14.
31. Ohno Y, Suda K, Masuko K, Yagi H, Hashimoto Y, Masuko T. Production and characterization of highly tumor-specific rat monoclonal antibodies recognizing the extracellular domain of human L-type amino-acid transporter 1. Cancer Sci 2008; 99: 1000-7.
32. Tamura T, Chiba J. Production of antibodies against multipass membrane proteins expressed in human tumor cells using dendritic cell immunization. J Biomed Biotechnol 2009; 2009: 673098.
33. Ohno Y, Yagi H, Nakamura M, Masuko K, Hashimoto Y, Masuko T. Cell-death-inducing monoclonal antibodies raised against DT40 tumor cells: identification of chicken transferrin receptor as a novel cell-death receptor. Cancer Sci 2008; 99: 894-900.
34. Edinger AL, Thompson CB. Death by design: apoptosis, necrosis and autophagy. Curr Opin Cell Biol 2004; 16: 663-9.
35. Ohno Y, Yagi H, Nakamura M, Masuko K, Hashimoto Y, Masuko T. Simultaneous induction of apoptotic, autophagic, and necrosis-like cell death by monoclonal antibodies recognizing chicken transferrin receptor. Biochem Biophys Res Commun 2008; 36: 775-81.
36. Shindelman JE, Ortmeyer AE, Sussman HH. Demonstration of the transferrin receptor in human breast cancer tissue. Potential marker for identifying dividing cells. Int J Cancer 1981; 27: 329-34.
37. Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML. The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin immunol 2006; 121: 144-58.
38. Moura IC, Lepelletier Y, Arnulf B et al. A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients. Blood 2004; 103: 1838-45.
39. Haynes BF, Hemler ME, Mann DL et al. Characterization of a monoclonal antibody (4F2) that binds to human monocytes and to a subset of activated lymphocytes. J Immunol 1981; 126: 1409-14.
40. Masuko T, Abe J, Yagita H, Hashimoto Y. Human bladder cancer cell-surface antigens recognized by murine monoclonal antibodies raised against T24 bladder cancer cells. Jpn J Cancer Res 1985; 76: 386-94.
41. Hashimoto Y, Masuko T, Yagita H, Endo N, Kanazawa J, Tazawa J. A proliferation-associated rat cell surface antigen recognized by a murine monoclonal antibody. Gann 1983; 74: 819-21.
42. Bron C, Rousseaux M, Spiazzi AL, MacDonald HR. Structural homology between the human 4F2 antigen and a murine cell surface glycoprotein associated with lymphocyte activation. J Immunol 1986; 137: 397-9.
43. Kaira K, Oriuchi N, Imai H et al. Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma. Lung Cancer 2009; 66: 120-6.
44. Kaira K, Oriuchi N, Imai H et al. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer 2008; 98: 742-8.
45. Yagita H, Masuko T, Hashimoto Y. Inhibition of tumor cell growth in vitro by murine monoclonal antibodies that recognize a proliferation-associated cell surface antigen system in rats and humans. Cancer Res 1986; 46: 1478-84.
46. Hara K, Kudoh H, Enomoto T, Hashimoto Y, Masuko T. Malignant transformation of NIH3T3 cells by overexpression of early lymphocyte activation antigen CD98. Biochem Biophys Res Commun 1999; 262: 720-5.
47. Shishido T, Uno S, Kamohara M et al. Transformation of BALB3T3 cells caused by over-expression of rat CD98 heavy chain (HC) requires its association with light chain: mis-sense mutation in a cysteine residue of CD98HC eliminates its transforming activity. Int J Cancer 2000; 87: 311-6.
48. Hara K, Kudoh H, Enomoto T, Hashimoto Y, Masuko T. Enhanced tumorigenicity caused by truncation of the extracellular domain of GP125/CD98 heavy chain. Oncogene 2000; 19: 6209-15.
49. Mastroberardino L, Spindler B, Pfeiffer R et al. Amino-acid transport by heterodimers of 4F2hc/CD98 and members of a permease family. Nature 1998; 395: 288-91.
50. Pineda M, Fernandez E, Torrents D et al. Identification of a membrane protein, LAT-2, that co-expresses with 4F2 heavy chain, an L-type amino acid transport activity with broad specificity for small and large zwitterionic amino acids. J Biol Chem 1999; 274: 19738-44.
51. Torrents D, Estevez R, Pineda M et al. Identification and characterization of a membrane protein (y+L amino acid transporter-1) that associates with 4F2hc to encode the amino acid transport activity y+L. A candidate gene for lysinuric protein intolerance. J Biol Chem 1998; 273: 32437-45.
52. Pfeiffer R, Rossier G, Spindler B, Meier C, Kuhn L, Verrey F. Amino acid transport of y+L-type by heterodimers of 4F2hc/CD98 and members of the glycoprotein-associated amino acid transporter family. EMBO J 1999; 18: 49-57.
53. Fukasawa Y, Segawa H, Kim JY et al. Identification and characterization of a Na(+)-independent neutral amino acid transporter that associates with the 4F2 heavy chain and exhibits substrate selectivity for small neutral D- and L-amino acids. J Biol Chem 2000; 275: 9690-8.
54. Sato H, Tamba M, Ishii T, Bannai S. Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J Biol Chem 1999; 274: 11455-8.
55. Sang J, Lim YP, Panzica M, Finch P, Thompson NL. TA1, a highly conserved oncofetal complementary DNA from rat hepatoma, encodes an integral membrane protein associated with liver development, carcinogenesis, and cell activation. Cancer Res 1995; 55: 1152-9.
56. Wolf DA, Wang S, Panzica MA, Bassily NH, Thompson NL. Expression of a highly conserved oncofetal gene, TA1/E16, in human colon carcinoma and other primary cancers: homology to Schistosoma mansoni amino acid permease and Caenorhabditis elegans gene products. Cancer Res 1996; 56: 5012-22.
57. Yanagida O, Kanai Y, Chairoungdua A et al. Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta 2001; 1514: 291-302.
58. Rennie MJ, Bohe J, Smith K, Wackerhage H, Greenhaff P. Branched-chain amino acids as fuels and anabolic signals in human muscle. J Nutr 2006; 1(Suppl): 264S-8S.
59. Tomiya T, Omata M, Fujiwara K. Significance of branched chain amino acids as possible stimulators of hepatocyte growth factor. Biochem Biophys Res Commun 2004; 313: 411-6.
60. Ishida I, Tomizuka K, Yoshida H et al. Production of human monoclonal and polyclonal antibodies in TransChromo animals. Cloning Stem Cells 2002; 4: 91-102.
61. Park SY, Gonen M, Kim HJ, Michor F, Polyak K. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest 2010; 120: 636-44.
62. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006; 12: 1167-74.
63. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8: 755-68.
64. Ishimoto T, Oshima H, Oshima M et al. CD44+ slow-cycling tumor cell expansion is triggered by cooperative actions of Wnt and prostaglandin E2 in gastric tumorigenesis. Cancer Sci 2010; 101: 673-8.
65. Nishimura T, Nakamura Y, Tsukamoto H et al. Human c-erbB-2 proto-oncogene product as a target for bispecific-antibody-directed adoptive tumor immunotherapy. Int J Cancer 1992; 50: 800-4.
66. Suzuki S, Uno S, Fukuda Y, Aoki Y, Masuko T, Hashimoto Y. Cytotoxicity of anti-c-erbB-2 immunoliposomes containing doxorubicin on human cancer cells. Br J Cancer 1995; 72: 663-8.
67. Masuko T, Sugahara K, Kozono M et al. A murine monoclonal antibody that recognizes an extracellular domain of the human c-erbB-2 protooncogene product. Jpn J Cancer Res 1989; 80: 10-4.
68. Asamoto M, Hasegawa R, Masuko T et al. Immunohistochemical analysis of c-erbB-2 oncogene product and epidermal growth factor receptor expression in human urinary bladder carcinomas. Acta Pathol Jpn 1990; 40: 322-6.
69. Itoh K, Inoue K, Tezuka T et al. Molecular structural and functional characterization of tumor suppressive anti-ErbB-2 monoclonal antibody by phage display system. J Biochem 2003; 133: 239-45.
70. Itoh K, Inoue K, Hirooka K et al. Phage display cloning and characterization of monoclonal antibody genes and recombinant Fab fragment against the CD98 oncoprotein. Jpn J Cancer Res 2001; 92: 1313-21.
71. Itoh K, Inoue K, Hayashi H, Suzuki T, Masuko T. Identification of cell proliferation-associated epitope on CD98 oncoprotein using phage display random peptide library. Cancer Sci 2007; 98: 1696-700.
72. Itoh K, Ohshima M, Sonobe M et al. Antibody epitope peptides as potential inducers of IgG antibodies against CD98 oncoprotein. Cancer Sci 2009; 100: 126-31.
73. Riemer AB, Kurz H, Klinger M et al. Vaccination with Cetuximab mimotopes and biologcal properties of induced anti-epidermal growth factor receptor antibodies. J Natl Cancer Inst 2005; 97: 1663-70.
74. Haller BK, Brave A, Wallgard E et al. Therapeutic efficacy of a DNA vaccine targeting the endothelialtip cell antigen delta-like ligand 4 in mammary carcinoma. Oncogene 2010; 29: 4276-86.
75. Klaus S, Behrends J, Borowski A et al. Blockade of interleukin-13-mediated cell activation by a novel inhibitory antibody to human IL-13 receptor alpha 1. Mol Immunol 2006; 43: 1799-807.
76. Ni Y, Ma K, Ni J, Zheng X, Wang Y, Xiong S. Rapid and simple approach to preparation of monoclonal antibody based on DNA immunization. Cell Mol Immunol 2004; 1: 295-9.
77. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Imunology 2010; 10: 317-27.
78. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006; 6: 714-27.
79. Tanaka T, Masuko T, Hashimoto Y. Appearance of a proliferation-associated antigen, gp125, on rat and human lymphocytes by co-stimulation with phorbol ester and calcium ionophore. J Biochem 1988; 103: 644-9.
80. Cosman DA. Family of ligands for the TNF receptor superfamily. Stem Cells. 1994; 12: 440-55.